BRIA-OTS cellular immunotherapy for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This study tests an investigational cellular immunotherapy called BRIA-OTS for people with metastatic breast cancer that has spread and is no longer responding to standard treatments. It aims to help the immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic breast cancer that has gotten worse even after trying standard treatments.
- You are 18 years or older.
- Your doctor expects you to live at least 4 more months.
- You are well enough to do daily activities on your own or with minimal help (ECOG 0, 1, or 2).
- You have recovered from side effects of previous treatments (except for hair loss, well-controlled hormone issues, or mild anemia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for metastatic triple-negative breast cancer, using radiation to stimulate the immune system, an immunotherapy drug (pembrolizumab), and a medication that targets immune-suppressing cells. The goal is to boost the body's response to immunotherapy, especially in people who have already received immunotherapy but saw limited benefit.
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
This trial tests whether combining the immunotherapy drug toripalimab with targeted radiation can help patients with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. It aims to find a new treatment option for these patients.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.